用低剂量塔克罗利斯避免使用类固醇,对于接受脏移植的人来说,在长期内是安全有效的
Jana Ekberg1, Anna-Elisabeth Aagaard Enevoldsen2, Carin Wallquist3
1Transplant Institute, Sahlgrenska University Hospital, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Kidney international reports
|September 22, 2025
概括
避用类固醇 (SA) 对于低免疫风险的移植接受者来说是安全有效的,长达7年. 这种使用低剂量塔克罗利斯的策略维持了移植存活率和功能,同时减少了移植后的糖尿病.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 移植 移植 移植 移植
背景情况:
- 在此之前,SAILOR研究已经证明了在移植后2年内在低风险接受者中避免使用类固醇 (SA) 的可行性,安全性和有效性.
- 长期数据对于验证使用低剂量塔克罗利斯的SA协议的延长安全性和有效性至关重要.
研究的目的:
- 评估移植接受者的类固醇避免 (SA) 协议的长期结果.
- 为了评估SA的安全性和有效性,移植后长达7年.
主要方法:
- 来自最初的SAILOR试验的215名参与者的后续观察性研究.
- 临床数据采集于1,2,5年,以及最后一次随访 (平均7.3年).
主要成果:
- 在7.3年后,SA和标准护理手臂之间,死亡审查的移植存活率,患者存活率,活检证明的排斥率或估计的淋巴细胞过率 (eGFR) 没有显著差异.
- 在SA手臂中,移植后糖尿病发病率显著降低.
- 在SA组的三分之二的参与者在随访结束时仍然没有使用类固醇;严重的感染和恶性瘤没有显著差异.
结论:
- 避用类固醇 (SA) 是一种安全有效的策略,适用于低免疫风险的移植接受者,长达7岁.
- 低剂量塔克罗利斯的SA策略支持持续的移植存活,患者存活和功能.
- 酸盐可以降低移植后糖尿病的风险,而不会增加严重的感染或恶性瘤.
相关概念视频
01:26Kidney Transplant II: Surgical Procedure
320
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
320
01:28Kidney Transplant I: Introduction
345
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
345
01:16Kidney Transplant III: Nursing Management
318
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
318
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
177
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
177
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
439
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
439